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Edited by Frances ShannonAbstract A nuclear localization sequence (NLS) in the type II
interferon (IFN) IFNc, which is responsible for the nuclear
translocation of both the ligand and the a-subunit (IFNGR1)
of the receptor complex, has previously been characterized and
its role in signaling examined in detail. We have now identiﬁed
an NLS in the type I IFN receptor (IFNAR) common subunit IF-
NAR1 from humans and show that the human IFNAR1 subunit
can translocate to the nucleus following human IFNb stimula-
tion. An NLS in human IFNAR1 is located in the extracellular
domain of IFNAR1 within the sequence 382RKIIEKKT (num-
bered for the precursor form). Nuclear import by the NLS func-
tions in a conventional fashion requiring cytosolic import factors,
is energy-dependent and inhibited by the prototypical NLS of the
SV40 large T-antigen. These studies provide a mechanism for
nuclear import of IFNAR1, as well as for type I IFN ligands,
and a starting point for studying an alternate role for IFNAR1
in nuclear signaling within the type I IFN system.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.1. Introduction
An alternate mode of signaling to the nucleus by diverse
cytokines, growth factors and hormones has been known for
some time that involves the direct nuclear translocation of lig-
ands and/or their receptors [1]. These ligand/receptor systems
now include, but are not limited to, those of growth hormone
[2,3], members of the epidermal growth factor family [4],
angiotensin [5], prolactin [6], interleukin-5 [7,8], FGFs [9],
and interferon-gamma (IFNc) [10,11]. In many of these cases,
the nuclear ligand or receptor has been identiﬁed as acting as a
transcription factor or transcriptional co-activator, thereby
highlighting a direct role for these nuclear ligand/receptor mol-
ecules in regulating gene expression.
In the case of the IFNs, the type II IFN IFNc has been de-
scribed as a nuclear localizing ligand [12,13]. The mechanism
and function of nuclear translocation of IFNc has been stud-
ied in detail [10,11]. IFNc has been shown to contain a nuclear
localization sequence (NLS) in its C-terminus that mediatesq This work is supported by NIH Grant AI56152 to H.M.J. This
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R-10573.
*Corresponding author. Present address: Bldg 71, Schmidt Biomedical
Science Center, Scripps Research Institute, 777 Glades Rd FAU, Boca
Raton, FL 33431, USA. Fax: +1 561 297 0329.
E-mail address: prem@scripps.edu (P.S. Subramaniam).
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.10.085the nuclear translocation of not only the ligand but also the
a-subunit of the IFNc receptor (IFNGR-1) [14]. The IFNc/
IFNGR-1 complex appears to function as a nuclear chaperone
for the STAT-1a transcription factor activated by IFNc
[10,11,14].
Within the type I IFN system, the a-subunit of the common
type I IFN receptor (IFNAR1) for the large family of type I
IFNs has been postulated to contain a putative NLS,
382RKIIEKKT (numbering for precursor form), within its
extracellular domain but this has not been experimentally tested
[1]. The IFNAR1 subunit is considered the signaling subunit,
as it does not bind type I IFNs with detectable aﬃnity but is
absolutely required for signal transduction from the heterodi-
meric IFNAR complex and for type I IFN biological activity
[15]. In contrast, the b-subunit, IFNAR2, appears to be the sub-
unit that binds type I IFNs with relatively high aﬃnity [15].
Signaling to the nucleus from the IFNAR complex occurs along
multiple pathways, one of which is the well characterized JAK/
STAT pathway (for reviews see [16–18]). In the JAK/STAT
pathway, IFNAR1 associates with the Janus kinase (Jak) family
member, Tyk2, while IFNAR2 associates with the Jak family
member, Jak1, which together activate STAT transcription fac-
tors as important nuclear messengers. Besides this pathway, IF-
NAR1 through the Jaks participates in activating other
pathways like those involving protein kinase C [19,20], insulin
receptor substrate proteins and PI 3 0-kinase [16,17], and p38
MAP kinase pathway [16,17], that may involve cross-talk with
the STAT pathway. However, the multiple pathways activated
by the type I IFNAR complex is a complicating feature since, as
has been previously suggested [11,10,21], almost all cytokines,
growth factors and hormones activate some or all of the same
pathways, raising the question of how signaling speciﬁcity in
the nucleus is ultimately maintained. The nuclear translocation
of ligands and/or their receptors and their emerging roles in
transcription and other chromatin events regulating gene
expression has been suggested as one method of imparting a de-
gree of speciﬁcity to nuclear signaling, since the nuclear messen-
ger is the signal generating ligand/receptor itself [10,11,21].
We show for the ﬁrst time in this study that within the type I
IFN system, the IFNAR1 subunit of the IFNAR complex is
translocated to the nucleus following ligand stimulation. Fur-
ther, we show that a NLS lies in the extracellular domain re-
gion of IFNAR1 containing the sequence 382RKIIEKKT
that was previously postulated. IFNAR1, thus, behaves simi-
larly to other receptors like c-ErbB-3, FGFR-1, Notch and
angiontensin II type I receptor that have been shown to be ac-
tively transported to the nucleus via NLSs in their sequence,
and is, thus, at least one component within the type I IFNation of European Biochemical Societies.
Table 1
Sequences of peptides used in this study
Peptide Sequencea
IFNAR1(374–390) cWENTSNAERKIIEKKTD
SV40 NLS cGGGPKKKRKVED
IFNc(95–125) cAKFEVNNPQVQRQAFNELIRVVHQLLPESSL
aA cysteine (underlined) was introduced as the ﬁrst amino acid residue
of each peptide sequence to allow for coupling to APC, where re-
quired. The IFNAR1 sequence is from the precursor form of human
IFNAR1 and that of IFNc from the mature form of murine IFNc, and
residues in peptides are numbered after the ﬁrst cysteine.
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ling through nuclear translocation.Fig. 1. Nuclear translocation of the human IFNAR1 subunit follow-
ing IFNb stimulation of cells. LpZRabL.10 cells grown on slides were
left untreated (A), or treated with 3000 U/ml of recombinant human
IFNb (B) or recombinant human IFNc (C) at 37 C for 1 h. Cells were
then ﬁxed and immunoﬂuorescently stained with antibodies to
IFNAR1.2. Materials and methods
2.1. Cell culture
The LpZRabL.10 clone expressing the IFNAR1 subunit and the
long form of the IFNAR2 subunit were a kind gift of Dr. O.R. Col-
amonici (University of Illinois, Chicago, IL), and have previously been
described [22]. WISH cells were grown in EMEM containing 10% fetal
bovine serum.
2.2. Peptide synthesis
Peptides used in this study (see Table 1) were synthesized on a
PerSeptive Biosystems 9050 automated peptide synthesizer using Fmoc
(N-(9-ﬂuorenyl)methoxycarbonyl) chemistry as outlined previously
[23].
2.3. Immunoﬂuorescent staining
LpZRabL.10 cells, or parental L 929 cells, were grown on micro-
scope slides and treated with 3000 U/ml of recombinant human or
murine IFNb (Biosource International, Camarillo, CA) for 1 h, before
ﬁxing and staining with antibodies to IFNAR1 (Santa Cruz Biotech-
nology, Santa Cruz, CA; #sc-845 recognizing both human and mouse
IFNAR1). Fixation and staining procedures were as described previ-
ously [24].
2.4. Preparation of import substrate (Allophycocyanin conjugation)
IFNAR1(374–390) peptide was coupled to SMCC-activated allo-
phycocyanin (APC; Prozyme, San Leandro, CA) using a molar ratio
of 4:1 peptide:APC as previously described [25,14] except that reduced
peptide was separated on Sephadex G-10 before addition to the acti-
vated APC.
2.5. Nuclear import assays
Nuclear import assays in digitonin-permeabilized WISH cells were
performed as previously described [25] using IFNAR1(374–390)-APC
as a substrate. Energy-dependence with respect to ATP and GTP
requirements was performed as before [25]. Competition experiments
with unlabeled peptides were also performed as before [25], except that
a 30-fold excess of unlabeled peptide was used.Fig. 2. The peptide IFNAR1(374–390) mediates the nuclear import of
the heterologous ﬂuorescent protein APC (IFNAR1-APC). Digitonin-
permeabilized WISH cells were incubated for the assay duration (30
min) with the complete import reaction mixture at 30 C (A) or 4 C
(B). In (C) cells were incubated with an import reaction mixture in
which the reticulocyte lysate was replaced by 4% BSA (w/v). (D) The
phase contrast image of the ﬁeld of cells in (C).3. Results and discussion
To ﬁrst determine whether the human IFNAR1 subunit
could translocate to the nucleus, we tested the subcellular
localization of human IFNAR1 in mouse L cells overexpress-
ing both human IFNAR1 and the long form IFNAR2 subunit
of the IFNAR receptor (clone LpZRabL.10 [22]). These cells
are fully responsive to both human IFNa and IFNb and have
been characterized previously [22]. Treatment of these cells
with human IFNb for 1 h followed by immunoﬂuorescent
staining for the IFNAR1 subunit showed a clear nuclear local-ization of the human IFNAR1 subunit (Fig. 1A and B). Treat-
ment with human IFNc did not induce nuclear localization of
human IFNAR1, showing the speciﬁcity of the response (Fig.
1C). LpZRabL.10 cells, or parental L 929 cells, treated with
murine IFNb (which does not activate the human IFNAR
complex) showed a weaker positive signal for nuclear murine
IFNAR1 (data not shown), as expected given the relatively
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in these cells.
To speciﬁcally examine the putative NLS in IFNAR1 for
nuclear localization properties, we used a standard ﬂuores-
cence-based nuclear import assay using digitonin-permeabi-
lized cells that are routinely used to study NLS function
[26–28], such as with the IFNc NLS [14,25,29] or that of the
prototypical SV40 large T-antigen NLS (SV40 NLS) [26–28].
For use as substrate in the assays, a peptide containing the se-
quence RKIIEKKT (see Table 1) was coupled to the autoﬂu-
orescent protein APC. As can be seen in Fig. 2A,
IFNAR1(374–390)-APC was translocated to the nucleus in
the complete nuclear import assay. The nuclear accumulation
was inhibited when the assay was run at 4 C (Fig. 2B) and
was also dependent on the presence of reticulocyte-derived
cytosolic factors (Fig. 2C). These data show that the IF-
NAR1(374–390) is an NLS that is capable of mediating the nu-
clear import of a heterologous protein (APC), which is typical
of many conventional NLSs.
Active nuclear import across the nuclear pore complex
(NPC) is energy-dependent and depends on the availability
of ATP and GTP. In the absence of ATP or GTP, bindingFig. 3. Nuclear import directed by IFNAR1(374–390) is strictly
energy-dependent. Permeabilized cells for assay were incubated, as in
Fig. 1A, either with the complete import mixture (A), or with an
import mixture that had been depleted of ATP as described under
Section 2 (B), or an import mixture in which exogenous GTP was
omitted, and the non-hydrolyzable analog, GTPcS, was included at a
ﬁnal concentration of 0.5 mM (D). (C) and (E) are phase contrast
images of the ﬁeld of cells in (B) and (D), respectively. IFNAR1-
APC=IFNAR1(374–390)-APC.to the NPC occurs without transport into the nucleus. As
can be seen in Fig. 3, the nuclear import of IFNAR1(374–
390)-APC was also strictly energy-dependent. Depletion of
ATP from cytosolic extracts blocked nuclear import of IF-
NAR1(374–390)-APC (compare Fig. 3A and B), and IF-
NAR1(374–390)-APC characteristically rimmed the nuclei
as it accumulated at the nuclear pores without further translo-
cation. Similarly, omission of GTP and inclusion of the non-
hydrolyzable analog GTPcS blocked nuclear import (Fig.
3D) with substrate rimming the nuclei. These data are typical
of conventional NLSs that function in active nuclear import
and show that the IFNAR1(374–390) shares these properties.
To further examine the speciﬁcity of IFNAR1(374–390)
NLS properties, we performed competition experiments with
unlabeled peptides in the above assays. The peptides used
(see Table 1 for sequences) were IFNAR1(374–390) itself, a
peptide including the SV40 NLS, and as a negative control,
peptide IFNc(95–125) derived from the C-terminus of IFNc
that has no NLS activity [25]. The SV40 NLS is one of the best
characterized conventional polybasic NLSs and has been
shown to utilize the Ran/importin pathway for nuclear import.
As shown in Fig. 4, nuclear import of IFNAR1(374–390)-APC
was inhibited by an excess of the unlabeled IFNAR1(374–390)
peptide, showing that import was speciﬁcally driven by the IF-
NAR1 peptide in IFNAR1(382–389)-APC (Fig. 4A and B).
The nuclear import of IFNAR1-APC was also inhibited by
an excess of a peptide containing the prototypical polybasic
SV40 NLS (Fig. 4C), but was not inhibited by the non-NLS
IFNc(95–125) control peptide (Fig. 4D). This suggests thatFig. 4. Nuclear import by IFNAR1(374–390) is peptide-speciﬁc and is
inhibited by the SV40 NLS. Import reaction mixtures containing the
substrate IFNAR1(374–390)-APC (IFNAR1-APC; 220 nM) were
incubated in the absence of any competitor peptides (A) or in the
presence of the following competitor peptides: the cognate peptide
IFNAR1(374–390) (B), the SV40 T-NLS peptide (C), or a non-NLS
control peptide IFNc(95–125) (D) (for sequences, see Table 1).
Competitor peptides were incubated at a 30-fold molar excess, with
respect to the substrate IFNAR1(374–390)-APC, in the reaction
mixture at room temperature for 5 min just before the addition of the
substrate and assay on mouse A31 cells.
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importin pathway that are utilized by the SV40 NLS peptide.
The above study identiﬁes for the ﬁrst time an NLS domain
within a component of the type I IFN system, namely the
receptor subunit IFNAR1. Previous studies have already iden-
tiﬁed an NLS in the type II IFN IFNc and have examined in
detail its role in signaling [11,10]. The NLS of IFNAR1 lies
within the extracellular domain of the human IFNAR1. This
region appears to function as a conventional NLS in a manner
similar to that of the SV40 NLS. In this regard, the IFNAR1
NLS contains basic residues interspersed with hydrophobic
residues. This is broadly similar to the well characterized
NLS of the c-myc protein, AAKRVKLD [30], where hydro-
phobic residues were found to enhance nuclear localization
[31]. The c-myc NLS also utilizes the Ran/importin pathway
similar to the SV40 NLS [32]. The speciﬁc contributions of
individual residues in the IFNAR1 NLS remain to be deter-
mined. This report also documents the fact that the IFNAR1
subunit is capable of translocating to the nucleus following lig-
and (IFNb) stimulation. These studies provide a framework
for further detailed study of an alternate mode of signaling
to the nucleus within the type I IFN system.4. Note added in proof
A recent report [33] has shown that the second chain of the
type I IFN receptor complex, IFNAR2, is subject to regulated
intramembrane proteolysis and the intracellular cytoplasmic
domain (ICD) of IFNAR2 is translocated to the nucleus.
Although the NLS for this translocation was not identiﬁed,
the nuclear ICD can function as a repressor of transcription
from the Interferon Stimulated Response Element, ISRE, in
gene promoters.
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